| dbo:abstract |
Nancy A. Thornberry is the founding CEO and current Chair, R&D at Kallyope Inc. in New York City. She previously worked with Merck Research Laboratories (MRL), joining the company in 1979 as a biochemist and retiring from the position of Senior Vice President and Franchise Head, Diabetes and Endocrinology in 2013. In 1992, Thornberry identified the first caspase, Caspase-1/Interleukin-1 converting enzyme (ICE). In 1999, Thornberry initiated Merck's research into dipeptidyl peptidase-4, leading to the development of FDA-approved treatments for Type 2 diabetes. She has received a number of awards, including the 2011 PhRMA Discoverer’s Award. (en) |
| dbo:almaMater |
dbr:Muhlenberg_College |
| dbo:nationality |
dbr:United_States |
| dbo:residence |
dbr:United_States |
| dbo:thumbnail |
wiki-commons:Special:FilePath/Nancy_A._Thornberry_at_SCI-Perkin-Medal-2017-007.jpg?width=300 |
| dbo:wikiPageExternalLink |
https://www.youtube.com/watch%3Fv=ByJsKyZ1oyo https://www.youtube.com/watch%3Fv=jIIGnApUZNE |
| dbo:wikiPageID |
55519401 (xsd:integer) |
| dbo:wikiPageLength |
16689 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1113837847 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:Ann_E._Weber dbr:Hypertension dbr:United_States dbr:Enzymology dbc:21st-century_American_women dbc:Living_people dbc:Year_of_birth_missing_(living_people) dbr:Monocytes dbr:Muhlenberg_College dbr:Apoptosis dbr:Lisinopril dbr:Sitagliptin dbr:CEO dbc:American_women_chemists dbr:Type_2_diabetes dbr:ACE_inhibitor dbr:Allentown,_Pennsylvania dbr:Cysteine_protease dbr:Ezetimibe dbr:FDA dbr:Fertility dbr:Osteoporosis dbr:Dipeptidyl_peptidase-4 dbr:NPC1L1 dbc:21st-century_American_chemists dbc:American_women_chief_executives dbc:Muhlenberg_College_alumni dbr:Diabetes dbr:South_Bend,_Indiana dbr:Intarcia_Therapeutics dbr:Metformin dbr:Obesity dbr:Caspase dbr:Caspase_1 dbr:Rahway,_New_Jersey dbr:Merck_Research_Laboratories dbr:Serine_hydrolase dbr:Contraception dbr:Abide_Therapeutics |
| dbp:align |
right (en) |
| dbp:almaMater |
dbr:Muhlenberg_College |
| dbp:awards |
2011 (xsd:integer) |
| dbp:caption |
Nancy Thornberry, 2017 (en) |
| dbp:field |
Metabolic disorders, Drug discovery (en) |
| dbp:name |
Nancy Ann Thornberry (en) |
| dbp:nationality |
dbr:United_States |
| dbp:residence |
dbr:United_States |
| dbp:video |
“Bench to bedside -- discovery of JANUVIA (Sitagliptin)”, Ann Weber & Nancy Thornberry, TEDxNJIT (en) “PhRMA11 Discoverers Award Winner 2011”, PhRMAPress (en) |
| dbp:width |
210 (xsd:integer) |
| dbp:wikiPageUsesTemplate |
dbt:Authority_control dbt:External_media dbt:Quote dbt:Reflist dbt:Infobox_scientist |
| dbp:workInstitutions |
Kallyope Inc., Merck Research Laboratories (en) |
| dcterms:subject |
dbc:21st-century_American_women dbc:Living_people dbc:Year_of_birth_missing_(living_people) dbc:American_women_chemists dbc:21st-century_American_chemists dbc:American_women_chief_executives dbc:Muhlenberg_College_alumni |
| rdf:type |
owl:Thing foaf:Person dbo:Person dul:NaturalPerson wikidata:Q19088 wikidata:Q215627 wikidata:Q5 wikidata:Q729 dbo:Animal dbo:Eukaryote dbo:Scientist dbo:Species schema:Person wikidata:Q901 |
| rdfs:comment |
Nancy A. Thornberry is the founding CEO and current Chair, R&D at Kallyope Inc. in New York City. She previously worked with Merck Research Laboratories (MRL), joining the company in 1979 as a biochemist and retiring from the position of Senior Vice President and Franchise Head, Diabetes and Endocrinology in 2013. (en) |
| rdfs:label |
Nancy Thornberry (en) |
| owl:sameAs |
wikidata:Nancy Thornberry https://global.dbpedia.org/id/3uPD9 |
| prov:wasDerivedFrom |
wikipedia-en:Nancy_Thornberry?oldid=1113837847&ns=0 |
| foaf:depiction |
wiki-commons:Special:FilePath/Nancy_A._Thornberry_at_SCI-Perkin-Medal-2017-007.jpg |
| foaf:isPrimaryTopicOf |
wikipedia-en:Nancy_Thornberry |
| foaf:name |
Nancy Ann Thornberry (en) |
| is dbo:wikiPageDisambiguates of |
dbr:Thornberry |
| is dbo:wikiPageWikiLink of |
dbr:Ann_E._Weber dbr:Thornberry |
| is foaf:primaryTopic of |
wikipedia-en:Nancy_Thornberry |
